Post by CRYOPDP

New perioperative data in high-risk prostate cancer   Johnson & Johnson has shared Phase 3 PROTEUS results for apalutamide plus hormone therapy administered before and after prostate cancer surgery.   The study reported that patients were nine times more likely to have little to no cancer remaining at surgery, with a 20% lower risk of metastasis or death.   For CRYOPDP, the logistics angle is the trial's design. When treatment spans both sides of surgery, the timeline must be clear from the first dose through post-surgery follow-up, with medicines, study materials, records, and handovers remaining tied to the patient pathway.   Read the Johnson & Johnson release here: https://lnkd.in/e6Mb_W8K.   #ClinicalTrials #ProstateCancer #HighRiskProstateCancer #UrologicOncology #PerioperativeTherapy #NeoadjuvantTherapy #AdjuvantTherapy #ClinicalTrialLogistics #CRYOPDP